Impact of statin use on clinical outcomes in patients with heart failure

  • Bielecka-Dabrowa A & al.
  • Lipids Health Dis
  • 31 Oct 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.


  • Statin treatment was associated with reduction in all-cause mortality, cardiovascular (CV) mortality and CV hospitalisation in heart failure (HF) with either left ventricular ejection fraction (LVEF) ≥40% or LVEF
  • Lipophilic statins might be more favourable than hydrophilic statins for patients with HF.

Why this matters

  • The role of statins in patients with HF and different LVEF levels remains unclear, particularly because of the lack of data from randomised trials in non-ischaemic HF and taking into account potential prosarcopenic effects of statins.

Study design

  • Meta-analysis of 17 studies (n=88,100) compared the effects of statin (n=42,400) vs non-statin therapy (n=45,700) on clinical outcomes in patients with HF.
  • Primary outcomes: all-cause mortality and CV mortality and hospitalisation.
  • Funding: None.

Key results

  • Statin vs non-statin users were significantly at lower risk for:
    • all-cause mortality (HR, 0.77; 95% CI, 0.72-0.83; P<.0001 i>2=63%) and
    • CV mortality (HR, 0.82; 95% CI, 0.76-0.88; P<.00001 i>2=63%) and hospitalisation (HR, 0.78; 95% CI, 0.69-0.89; P=.0003).
  • Compared with non-statin users, statin users with both EF 2=71% and HR, 0.75; 95% Cl, 0.69-0.82; P<.00001 for both>
  • Similarly, the risk for CV mortality (HR, 0.83; 95% CI, 0.77-0.90; I2=55%; P<.00001 and hr ci p=".0003," respectively hospitalisations i>2=63%, respectively) reduced in both EF groups.
  • Lipophilic vs hydrophilic statins significantly decreased:
    • CV mortality (HR 0.79; 95% Cl, 0.74–0.88 vs HR 0.94; 95% Cl, 0.85–1.05),
    • CV hospitalizations (HR 0.60; 95% Cl, 0.45–0.86 vs HR 0.78; 95% Cl, 0.50–1.22).


  • Heterogeneity among studies.
  • Limited data available on compliance with statin therapy or statin dosage.